149 related articles for article (PubMed ID: 3206137)
61. Myasthenia Gravis.
Gilhus NE
N Engl J Med; 2016 Dec; 375(26):2570-2581. PubMed ID: 28029925
[No Abstract] [Full Text] [Related]
62. [Determination of anti-acetylcholine receptor antibodies in myasthenia and its treatment by plasma exchange and immunosuppressants].
Goulon M; Gajdos P; Goulon C; Bussel A; Morel E; Raimond F; Estournet B
C R Seances Soc Biol Fil; 1980; 174(4):467-78. PubMed ID: 6449232
[TBL] [Abstract][Full Text] [Related]
63. [Treatment of myasthenia gravis by plasma exchange and immunosuppressors].
Goulon M; Estournet B; Gajdos P; Bussel A; Goulon C
Rev Med Interne; 1980; 1(2):213-6. PubMed ID: 7256012
[No Abstract] [Full Text] [Related]
64. [Treatment of myasthenia gravis].
Matell G; von Reis G
Lakartidningen; 1973 Oct; 70(43):3821-5. PubMed ID: 4362569
[No Abstract] [Full Text] [Related]
65. [Cholinergic crisis in a patient with myasthenia treated by plasma exchange and anticholinesterase agents].
Pourrat O; Robert R; Neau JP; Deleplanque P; Alcalay D
Ann Med Interne (Paris); 1988; 139 Suppl 1():51-2. PubMed ID: 3247993
[TBL] [Abstract][Full Text] [Related]
66. [Inhalation anesthesia in myasthenic patients undergoing elective thymectomy].
Rubio Pascual P; Ibáñez Agüir V; Abades Alvarez J; Trueba JL
Rev Esp Anestesiol Reanim; 1988; 35(6):308-10. PubMed ID: 3238125
[No Abstract] [Full Text] [Related]
67. Myasthenia gravis: the unmet needs of a paradigmatic autoimmune disease.
Modrego PJ
Neurodegener Dis Manag; 2018 Jun; 8(3):137-139. PubMed ID: 29943694
[No Abstract] [Full Text] [Related]
68. [Current status of the physiopathology and treatment of myasthenia gravis].
Vázquez A; Fernández O
Rev Clin Esp; 1978 May; 149(4):321-6. PubMed ID: 694105
[No Abstract] [Full Text] [Related]
69. Diagnosis and management of autoimmune myasthenia gravis.
Angelini C
Clin Drug Investig; 2011; 31(1):1-14. PubMed ID: 21053987
[TBL] [Abstract][Full Text] [Related]
70. [Diagnosis and treatment of myasthenia gravis].
Ponseti J; Espín E; Armengol M
Med Clin (Barc); 2000 Sep; 115(7):264-70. PubMed ID: 11013152
[No Abstract] [Full Text] [Related]
71. Short and long-term clinical effects of plasma-exchange in 33 cases of myasthenia gravis.
Fornasari PM; Riva G; Piccolo G; Cosi V; Lombardi M
Int J Artif Organs; 1985 May; 8(3):159-62. PubMed ID: 4030134
[TBL] [Abstract][Full Text] [Related]
72. Novel therapies target myasthenia gravis.
Hampton T
JAMA; 2007 Jul; 298(2):163-4. PubMed ID: 17622589
[No Abstract] [Full Text] [Related]
73. [Reply].
Pitz S; Jordan B; Zierz S
Ophthalmologe; 2013 Dec; 110(12):1202. PubMed ID: 24482815
[No Abstract] [Full Text] [Related]
74. Treatment of myasthenic crisis in late life.
Sellman MS; Mayer RF
South Med J; 1985 Oct; 78(10):1208-10. PubMed ID: 4049040
[TBL] [Abstract][Full Text] [Related]
75. Steroid treatment for myasthenia gravis: steroids have an important role.
Bedlack RS; Sanders DB
Muscle Nerve; 2002 Jan; 25(1):117-21. PubMed ID: 11754196
[No Abstract] [Full Text] [Related]
76. Plasmapheresis for myasthenia gravis.
Newsom-Davis J; Vincent A; Wilson SG; Ward CD; Pinching AJ; Hawkey C
N Engl J Med; 1978 Feb; 298(8):456-7. PubMed ID: 622126
[No Abstract] [Full Text] [Related]
77. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy.
Prakash S; Hans R; Sharma RR; Lal V; Marwaha N
Neurol India; 2017; 65(6):1409-1412. PubMed ID: 29133726
[No Abstract] [Full Text] [Related]
78. The treatment of severe myasthenia gravis with immunosuppressive agents.
Mertens HG; Balzereit F; Leipert M
Eur Neurol; 1969; 2(6):321-39. PubMed ID: 4185500
[No Abstract] [Full Text] [Related]
79. [Characteristic movement disorders in myasthenic eye muscle paralysis].
Schmidt D
Ophthalmologe; 2013 Dec; 110(12):1201-2. PubMed ID: 24337208
[No Abstract] [Full Text] [Related]
80. Management of myasthenia gravis.
Lazar A
J Assoc Physicians India; 1991 Aug; 39(8):655. PubMed ID: 1814893
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
